𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Cytomegalovirus disease in African-American kidney transplant patients

✍ Scribed by J. McGee; V. Mave; C.L. Yau; M. Killackey; A. Paramesh; J. Buell; D.P. Slakey; L.L. Hamm; R. Zhang

Book ID
115100358
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
95 KB
Volume
14
Category
Article
ISSN
1398-2273

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cytomegalovirus prophylaxis with valganc
Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients
✍ Hugo Wéclawiak; Nassim Kamar; Catherine Mengelle; Joëlle Guitard; Laure Esposito 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB

## Abstract The aims of this prospective, open‐label, single‐center pilot study were to assess the efficacy and safety of human cytomegalovirus (HCMV) prophylaxis using valganciclovir in HCMV‐ seropositive kidney‐transplant patients to prevent HCMV infection and disease. Fifty‐one HCMV seropositive

African American Kidney Transplantation
African American Kidney Transplantation Survival
✍ Gregory E. Malat, Christine Culkin, Aniruddha Palya, Karthik Ranganna, Mysore S. 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 223 KB
Predictive factors for cytomegalovirus r
Predictive factors for cytomegalovirus reactivation in cytomegalovirus-seropositive kidney-transplant patients
✍ Nassim Kamar; Catherine Mengelle; Laure Esposito; Joëlle Guitard; Marion Mehrenb 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract The aims of the present study were to assess the incidence of cytomegalovirus (CMV) reactivation, and to determine the predictive factors for CMV reactivation in CMV seropositive kidney‐transplant patients. One hundred ninety CMV seropositive kidney‐transplant patients were included in